Amalgamated Bank’s Mustang Bio MBIO Stock Holding History

Amalgamated Bank’s Portfolio MBIO Stock Details MBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-12	Closed	-$9K	–	3134
2022 Q1	$9K	Buy	+12	New	+$9.86K	﹤0.01%	2975

Other funds holding MBIO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Amalgamated Bank's MBIO Position: Q2 2022 in Review

Amalgamated Bank sold out of Mustang Bio (MBIO) in Q2 2022, closing a stake of 12 shares — an estimated $9K sold.

Amalgamated Bank first reported a position in MBIO in Q1 2022 and held it in 1 quarter. The position peaked at $9K in Q1 2022. 71 funds tracked by Wall St. Rank hold MBIO as of Q2 2022.

Amalgamated Bank reported no remaining Mustang Bio position as of Q2 2022 after selling out during the quarter.
Amalgamated Bank sold 12 Mustang Bio shares in Q2 2022, an estimated $9K.
Amalgamated Bank first reported a position in Mustang Bio in Q1 2022 and held it in 1 quarter.
Amalgamated Bank's Mustang Bio position peaked at $9K in Q1 2022.
71 funds tracked by Wall St. Rank held Mustang Bio as of Q2 2022.

Based on Amalgamated Bank's 13F filing for Q2 2022, filed 15 Aug 2022.